(Q36615314)

15 August 2017

1 reference

title

Management of hand-foot syndrome induced by capecitabine (English)

1 reference

chemotherapy-induced acral erythema

15 August 2017

main subject

1 reference

Sarah M Gressett

1

1 reference

15 August 2017

Brad L Stanford

series ordinal

2

1 reference

15 August 2017

Fred Hardwicke

series ordinal

3

1 reference

15 August 2017

publication date

1 September 2006

1 reference

Journal of Oncology Pharmacy Practice

15 August 2017

published in

1 reference

15 August 2017

volume

12

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

131-141

1 reference

Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Capecitabine as adjuvant treatment for stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Pyridoxine for the palmar-plantar erythrodysesthesia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206069242

21 January 2018

Identifiers

DOI

10.1177/1078155206069242

1 reference

15 August 2017

1 reference